From huge advances in cancer therapies and immune system modulation to recent developments in Immune checkpoints, T-Cell biology, neurological applications, treating infectious disease to creating vaccines: antibody based drugs are set to have profound effects in every area of medicine in the very near future.
Covering everything from discovery and development to getting an antibody to market: an innovative, forward looking and forward thinking conference programme is a key feature of the European Antibody Congress 2016. Which is why we work so hard to get it right. Based on direct research with pharma, biotech, non-profit, and academic experts in the antibody sector, the agenda is sure to cover the hottest topics for the audience.
14th November Day 1
15th November Day 2
16th November Day 3
Immunotherapy drugs are considered to be more efficient than the traditional options, and they are set to be used for the treatment of a variety (around 60%) of cancer types during the next ten years. Using T-Cells to reengage the body’s immune system has been more and more widely reported and is set to revolutionise the way cancer is treated.
A focused session looking at developing immune checkpoint antibodies as well as how to get T-Cell therapies from bench to bedside and more will take place this year. We will look at developing novel immunotherapies and how they behave in the clinic with case studies from Novartis, Roche and Memorial Sloan Kettering Hospital as well as a very special presentation from Pfizer discussing their new immunotherapy for the first time.
The major challenges of developing ADCs from tackling the bottleneck from bench to bedside will be addressed. Looking at novel payloads, decreasing side effects, target identification and preclinical development. An overview of the field will be given by Peter Senter from Seattle Genetics and followed by informative case studies from NBE Therapeutics, Oxford Biotherapeutics and other leading minds in the field from both pharma and biotech.
Focusing on the next generation of cancer application and autoimmune disease therapies. We will look at the mechanism of action of bispecifics in humans, new technologies, novel constructs and engineering bispecifics while considering later stages of clinical application.
New methods and technologies will be explored, such as advances in computational biology, analytics, and target discovery. Mass spectrometry, molecular assessment, structural analysis, stability and scalability will all be discussed. We will explore what the most important factors are in developing antibodies of every format from mAbs to ADCs with a view to clinical success and commercialisation.
Addressing the challenges of developing a molecule which is stable producible and has a high yield. Experts will discuss developing biologics from start to finish, ensuring GMP and quality at a commercial scale, new animal models, and stability. Manufacture and purification of ADCs, continuous manufacture of antibodies as well as new cost effective methods of antibody purification will also be covered.
How to ensure clinical viability of antibody drugs will be the focus of this session with case studies from the leading researchers, clinical oncologists and thought leaders. Topics such as ensuring clinical development through innovative partnering, considering immunogenicity, and decreasing costs in trials will be discussed.
A new targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development will take place.
From huge advances in cancer therapies and immune system modulation to recent developments in T-Cell biology, neurological applications, treating infectious disease to creating vaccines: antibody based drugs are set to have profound effects in every area of medicine in the very near future. We will be looking to the future of new targets, constructs and applications in 2016.
For more information